Genetic variants of the human dipeptide transporter PEPT1

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Genetic variants of the human dipeptide transporter PEPT1. / Anderle, Pascale; Nielsen, Carsten Uhd; Pinsonneault, Julia; Krog, Pernille Lindskov; Brodin, Birger; Sadée, Wolfgang.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 316, No. 2, 01.02.2006, p. 636-646.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Anderle, P, Nielsen, CU, Pinsonneault, J, Krog, PL, Brodin, B & Sadée, W 2006, 'Genetic variants of the human dipeptide transporter PEPT1', Journal of Pharmacology and Experimental Therapeutics, vol. 316, no. 2, pp. 636-646. https://doi.org/10.1124/jpet.105.094615

APA

Anderle, P., Nielsen, C. U., Pinsonneault, J., Krog, P. L., Brodin, B., & Sadée, W. (2006). Genetic variants of the human dipeptide transporter PEPT1. Journal of Pharmacology and Experimental Therapeutics, 316(2), 636-646. https://doi.org/10.1124/jpet.105.094615

Vancouver

Anderle P, Nielsen CU, Pinsonneault J, Krog PL, Brodin B, Sadée W. Genetic variants of the human dipeptide transporter PEPT1. Journal of Pharmacology and Experimental Therapeutics. 2006 Feb 1;316(2):636-646. https://doi.org/10.1124/jpet.105.094615

Author

Anderle, Pascale ; Nielsen, Carsten Uhd ; Pinsonneault, Julia ; Krog, Pernille Lindskov ; Brodin, Birger ; Sadée, Wolfgang. / Genetic variants of the human dipeptide transporter PEPT1. In: Journal of Pharmacology and Experimental Therapeutics. 2006 ; Vol. 316, No. 2. pp. 636-646.

Bibtex

@article{d589306534ef4cabac1d665d79c8ca90,
title = "Genetic variants of the human dipeptide transporter PEPT1",
abstract = "We tested whether genetic polymorphisms affect activity of the dipeptide transporter PEPT1, which mediates bioavailability of peptidomimetic drugs. All 23 exons and adjoining intronic sections of PEPT1 (SLC15A1) were sequenced in 247 individuals of various ethnic origins (Coriell collection). Of 38 single nucleotide polymorphisms (SNPs), 21 occurred in intronic and non-coding regions and 17 in exonic coding region, of which nine were nonsynonymous. Eight nonsynonymous variants were cloned into expression vectors and functionally characterized after transient transfection into Cos7 and Chinese hamster ovary cells. None of the variants had altered transport activity for various ligands, supporting previous results, except for the new, low-frequency PEPT1-F28Y. This variant displayed significantly reduced cephalexin uptake attributable to increased Km. Altered pH dependence of substrate transport suggested a role for F28Y in H+-driven translocation. Haplotype analysis revealed significant differences among ethnic populations. To search for cis-acting polymorphisms affecting transcription and mRNA processing, we measured allelic PEPT1 mRNA expression in human intestinal biopsy samples using a frequentmarker SNP in exon 17. Of 24 heterozygous samples, significant differences in allelic mRNA levels of 20 to 30% were observed in seven tissues. However, the small difference suggests that cis-acting regulatory factors have only limited effects on transporter activity. We also measured the relative formation of a splice variant (PEPT1-RF). PEPT1-RF mRNA levels ranged from 2 to 44% of total PEPT1-related mRNA, with potential consequences for drug absorption. Together with previous results, this study reveals a relatively low level of genetic variability in polymorphisms affecting both protein function and gene regulation.",
author = "Pascale Anderle and Nielsen, {Carsten Uhd} and Julia Pinsonneault and Krog, {Pernille Lindskov} and Birger Brodin and Wolfgang Sad{\'e}e",
year = "2006",
month = feb,
day = "1",
doi = "10.1124/jpet.105.094615",
language = "English",
volume = "316",
pages = "636--646",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

RIS

TY - JOUR

T1 - Genetic variants of the human dipeptide transporter PEPT1

AU - Anderle, Pascale

AU - Nielsen, Carsten Uhd

AU - Pinsonneault, Julia

AU - Krog, Pernille Lindskov

AU - Brodin, Birger

AU - Sadée, Wolfgang

PY - 2006/2/1

Y1 - 2006/2/1

N2 - We tested whether genetic polymorphisms affect activity of the dipeptide transporter PEPT1, which mediates bioavailability of peptidomimetic drugs. All 23 exons and adjoining intronic sections of PEPT1 (SLC15A1) were sequenced in 247 individuals of various ethnic origins (Coriell collection). Of 38 single nucleotide polymorphisms (SNPs), 21 occurred in intronic and non-coding regions and 17 in exonic coding region, of which nine were nonsynonymous. Eight nonsynonymous variants were cloned into expression vectors and functionally characterized after transient transfection into Cos7 and Chinese hamster ovary cells. None of the variants had altered transport activity for various ligands, supporting previous results, except for the new, low-frequency PEPT1-F28Y. This variant displayed significantly reduced cephalexin uptake attributable to increased Km. Altered pH dependence of substrate transport suggested a role for F28Y in H+-driven translocation. Haplotype analysis revealed significant differences among ethnic populations. To search for cis-acting polymorphisms affecting transcription and mRNA processing, we measured allelic PEPT1 mRNA expression in human intestinal biopsy samples using a frequentmarker SNP in exon 17. Of 24 heterozygous samples, significant differences in allelic mRNA levels of 20 to 30% were observed in seven tissues. However, the small difference suggests that cis-acting regulatory factors have only limited effects on transporter activity. We also measured the relative formation of a splice variant (PEPT1-RF). PEPT1-RF mRNA levels ranged from 2 to 44% of total PEPT1-related mRNA, with potential consequences for drug absorption. Together with previous results, this study reveals a relatively low level of genetic variability in polymorphisms affecting both protein function and gene regulation.

AB - We tested whether genetic polymorphisms affect activity of the dipeptide transporter PEPT1, which mediates bioavailability of peptidomimetic drugs. All 23 exons and adjoining intronic sections of PEPT1 (SLC15A1) were sequenced in 247 individuals of various ethnic origins (Coriell collection). Of 38 single nucleotide polymorphisms (SNPs), 21 occurred in intronic and non-coding regions and 17 in exonic coding region, of which nine were nonsynonymous. Eight nonsynonymous variants were cloned into expression vectors and functionally characterized after transient transfection into Cos7 and Chinese hamster ovary cells. None of the variants had altered transport activity for various ligands, supporting previous results, except for the new, low-frequency PEPT1-F28Y. This variant displayed significantly reduced cephalexin uptake attributable to increased Km. Altered pH dependence of substrate transport suggested a role for F28Y in H+-driven translocation. Haplotype analysis revealed significant differences among ethnic populations. To search for cis-acting polymorphisms affecting transcription and mRNA processing, we measured allelic PEPT1 mRNA expression in human intestinal biopsy samples using a frequentmarker SNP in exon 17. Of 24 heterozygous samples, significant differences in allelic mRNA levels of 20 to 30% were observed in seven tissues. However, the small difference suggests that cis-acting regulatory factors have only limited effects on transporter activity. We also measured the relative formation of a splice variant (PEPT1-RF). PEPT1-RF mRNA levels ranged from 2 to 44% of total PEPT1-related mRNA, with potential consequences for drug absorption. Together with previous results, this study reveals a relatively low level of genetic variability in polymorphisms affecting both protein function and gene regulation.

U2 - 10.1124/jpet.105.094615

DO - 10.1124/jpet.105.094615

M3 - Journal article

C2 - 16258023

AN - SCOPUS:31144449787

VL - 316

SP - 636

EP - 646

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -

ID: 131735380